J. T. Coyle and G. Tsai, “The NMDA Receptor Glycine Modulatory Site: A Therapeutic Target for Improving Cognition and Reducing Negative Symptoms in Schizophrenia,” Psychopharmacology, Vol. 174, No. 1, 2004, pp. 32-38. http://dx.doi.org/10.1007/s00213-003-1709-2

has been cited by the following article:

• TITLE: Is the Current Diagnosis of Schizophrenia Useful or Harmful?

  AUTHORS: Javier Alvarez-Rodriguez, Sergio Alvarez-Silva, Iria Alvarez-Silva

  KEYWORDS: Antisocial Personality Disorder; Drug Abusers; Genetic Markers; Neurocognitive Deficits; Negative Syndrome; Positive Symptoms

  JOURNAL NAME: Open Journal of Medical Psychology, Vol.3 No.2, January 17, 2014

  ABSTRACT: In recent decades, evidence has appeared in various scientific fields—genetic, psychopharmacological, neuro-psychological, etc.—which makes it difficult to maintain the positive and negative syndrome of schizophrenia under one and the same diagnosis. On the other hand, there are social and legal reasons recommending the conception of these two syndromes as different entities. In this paper, we conduct appropriate bibliographical researches to reveal these evidences. We discuss these findings and conclude proposing the split of positive and negative syndromes of schizophrenia in two different disorders.